Ulwazi olubalulekile lokudakwa kwezidakamizwa
I-stribild (eyaziwa nangokuthiwa yi-quad pilill) yithebhulethi eyodwa, i-dose fixed-dose inhlanganisela yezidakamizwa ezinezidakamizwa ezine ezisetshenziswa ekwelapheni i-HIV:
- i-tenofovir , i-nucleotide reverse transcriptase inhibitor
- emtricitabine, i-nucleotide reverse transcriptase inhibitor yesibili
- i-elvitegravir , i- integrase inhibitor
- i-cobicistat , i- HIV booster
I-Stribild yamukelwa yi-US Food and Drug Administration (FDA) ngo-Agasti 2012 ukuze isetshenziswe kubantu abadala abaneminyaka engu-18 nangaphezulu abaqala izidambisigciwane ngokokuqala ngqa, noma kulabo abanegciwane lesandulela ngculaza abaye baphelelwa ngokugcwele (okungabonakali).
Ukuphepha nokusebenza kwe-Stribild kuhlolwe ku-1,408 iziguli ezikhulile ezingaphathwa kabi ezivivinyweni ezimbili zempilo eziyimpumputhe, ezenza ukuthi iStribild iphumelele futhi ibekezeleleke njenge- Atripla , esinye isidakamizwa esiphezulu sokulawulwa kwezidakamizwa esine-tenofovir, emtricitabine, ne- efavirenz .
Ngo-2016, ukubunjwa okusha kwesidakamizwa okuthiwa i- Genvoya kwavunyelwa i-FDA, esikhundleni se-tenofovir ngenhlobo entsha yesidakamizwa esibizwa ngokuthi i-tenofovir alafenamide (TAF), eyaziwa ukuthi ibe nemiphumela emibi kakhulu kanye nemithi ephansi yezidakamizwa.
Ukubunjwa
I-Stribild iyithebhulethi eluhlaza, ene-oblong, elinefilimu, enama-150mg we-elvitegravir, ama-150mg we-cobicistat, i-200mg ye-emtricitabine ne-300mg ye-tenofovir. Ihlanganiswa ne "GSI" ngakolunye uhlangothi futhi "i-1" equkethwe kwesikwele kwenye.
Isilinganiso
Ithebulethi eyodwa nsuku zonke ithathwe ngokudla. I-Stribild akufanele ithathwe nganoma yimuphi omunye umuthi we-antiretroviral osetshenziselwa ukuphatha i-HIV.
Okuqhamuka uma udla imishanguzo
Imithi emibi yemiphumela yezidakamizwa iye yaphawulwa ngeziguli ezithatha iStribild. Izenzakalo ezivame kakhulu, ezibikwe ezigulini ezingu-7 noma ngaphezulu, ziyi:
- I-nausea
- Uhudo
- Izinwele
- Amaphupho angavamile
Ukusebenzisana kwezidakamizwa noma ukungahambisani
I-Stribild akufanele ithathwe ngezidakamizwa noma izithako ezilandelayo:
- Imithi ye-Anti-migraine: I-Cafergot, i-Migergot, i-Ergostat, i- Ergotamine ye-Medihaler, i- Wigraine, i-Wigrettes, i- Ergotrate, i-Methergine, i-DHE 45
- Imithi elwa no-psychotic: i-Orap
- Imithi ye-cholestol-ukwehla kwesimiso: Zocor, Simcor, Vytorin, Mevacor, i-Advicor, i-Altoprev, i-Mevacor
- Imithi ye-Hepatitis B: Hepsera, Preveon
- Ama-prokinetic: Ukuphanga, Ukuphanga i-Propulsion Quicksolv
- Imithi ye-prostate: Uroxatral
- Imithi yokwelapha ngokweqile yegazi: Revatio
- Imithi elwa namagciwane e-Rifampin: I-Mycobutin, i-Rifater, i- Rifamate, i-Rimactane, i- Rifadin, i-Priftin
- Ukuzijabulisa: Ngokweqile, i-Halcion
- Wort St. John's Wort
Ukucabangela
I-Stribild ingaba yingxaki kubantu abanomlando wezinkinga zezinso. Sicela ucebise udokotela wakho ukuthi unezinkinga ezinjalo ngaphambi kokuthatha iStribild. Umsebenzi wezinso kufanele uvame ukuhlolwa ezigulini ezisiteshini. Yeka ukwelashwa kweziguli ezinegunya lokulinganisa lokudaliwe ngaphansi kwe-50mL / iminithi. Izidakamizwa ze-Nephrotoxic akumele ziqondiswe nge-Stribild.
Izithako ezimbili ezisebenzayo eStribild (tenofovir, emtricitabine) nazo ziyasebenza ngokutheleleka kwe- hepatitis B (HBV) . Uma unayo i-HBV futhi uyeka ukuthatha isithrifikhi, kuzodingeka uqaphele izinyimba zakho zesibindi izinyanga ezimbalwa njengoba ukuyeka kungase kubangele ukuthi i-HBV ivuleke.
Njengoba kunjalo wonke ama-antiretroviral regimens, i-NRTIs e-Stribild ihlotshaniswa nengozi encane ye-lactic acidosis, kanye nezinkinga zesibindi.
Uma uthola ukuphefumula; ukuhlanzeka nokuhlanza; ubuhlungu noma ukungalindelekile kwesisu; ukwehlisa nokukhathala; ubuthakathaka ezandleni nasemilenzeni; noma i-yellowing yesikhumba kanye / noma amehlo, shayela udokotela wakho ngokushesha. I-Lactic acidosis, ikakhulukazi, ingaba yingozi uma ingashiywa ingaphathwa.
Imithombo:
Ukuphathwa kwe-US nokuDrug. "I-FDA ivumela iphilisi entsha yokuhlanganiswa kwegciwane lesandulela ngculazi kwezinye iziguli." I-Silver Spring, e-Maryland; ukushicilelwa okukhishwe ngo-Agasti 27, 2012.
Wohl, D .; Cohen, C .; I-Gallant, i-J .; et al. "I-Elvitegravir / cobicistat / emtricitabine / i-tenofovir DF (STB) ine-efficacy ehlala isikhathi eside futhi ihlukanisa ukuphepha okude isikhathi eside nokubekezela okuhambisana ne-efavirenz / emtricitabine / i-tenofovir DF (ATR) ngeviki engu-144 ezigulini ze-HIV ezingahambi kahle." I-53th Interscience Conference mayelana nama-Antimicrobial Agents kanye ne-Chemotherapy (ICAAC). Denver, Colorado, ngoSepthemba 11, 1013; abstract H-672a.
Shalit, P .; I-Gallant, i-J .; Imishini, A .; et al. "Ukubekezelelana isikhathi eside kwe-elvitegravir / cobicistat / emtricitabine / tenofovir DF kuqhathaniswa ne-efavirenz / emtricitabine / tenofovir DF noma i-ritonavir-ekhuthazwe i-atazanavir kanye ne-emtricitabine / i-tenofovir DF kwizifundo ezingenayo i-HIV-1 engenayo yokwelashwa." I-53th Interscience Conference mayelana nama-Antimicrobial Agents kanye ne-Chemotherapy (ICAAC). Denver, Colorado; Ngo-September 11, 2013; abstract H-671.